Lurasidon
Structural formula | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | |||||||||||||||||||
Non-proprietary name | Lurasidon | ||||||||||||||||||
other names |
|
||||||||||||||||||
Molecular formula | C 28 H 36 N 4 O 2 S | ||||||||||||||||||
External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
Drug information | |||||||||||||||||||
ATC code | |||||||||||||||||||
Drug class | |||||||||||||||||||
properties | |||||||||||||||||||
Molar mass | 492.68 g · mol -1 | ||||||||||||||||||
safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Lurasidone (trade name: Latuda ) is a drug that is indicated for the treatment of schizophrenia and depressive phases in the context of bipolar disorders . The substance is an atypical neuroleptic and was developed by the Japanese company Dainippon Sumitomo Pharma .
The antipsychotic effect of lurasidone is said to be based on a blockade of D 2 and 5-HT 2A receptors. In animal experiments, lurasidone was able to reverse the negative effects of the NMDA inhibitor MK-801 on the memory and learning ability of rats. The industry service Datamonitor sees lurasidone as another variant of atypical neuroleptics with limited additional therapeutic benefits.
Latuda has been approved in the US since 2010 and in the EU since March 2014 . In mid-2005, Dainippon out- licensed Sumitomo Lurasidon to the US company MSD Sharp & Dohme . However, Merck withdrew from the collaboration in 2006. Then Dainippon Sumitomo carried out the development himself again. In Germany , lurasidone was withdrawn from the market in March 2015.
See also
Web links
- Evaluation of the drug telegram
- Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for: Lurasidone
- Latuda: Off after four months - PHARMACY ADHOC
Individual evidence
- ↑ a b Registration dossier for 4,7-methano-1H-isoindole-1,3 (2H) -dione, 2 - [[(1R, 2R) -2 - [[4- (1,2-benzisothiazol-3-yl ) -1-piperazinyl] methyl] cyclohexyl] methyl] hexahydro-, (3aR, 4S, 7R, 7aS) - ( GHS section ) from the European Chemicals Agency (ECHA), accessed on July 7, 2020.
- ^ P. Cole, N. Serradell, E. Rosa, J. Bolos: Lurasidone hydrochloride. In: Drugs Fut. 33, 2008, pp. 316-322.
- ↑ T. Ishiyama, K. Tokuda, T. Ishibashi et al .: Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. In: Eur J Pharmacol . 572, 2007, pp. 160-70. PMID 17662268 .
- ↑ T. Enomoto, T. Ishibashi, K. Tokuda et al.: Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. In: Behav Brain Res. 186, 2008, pp. 197-207. PMID 17881065 .
- ↑ Datamonitor (July 2006). Pipeline Insight: Schizophrenia. ( Memento of March 22, 2014 in the Internet Archive ) (PDF file; 379 kB) Accessed November 3, 2008.
- ↑ US FDA: FDA approves Latuda to treat schizophrenia in adults (press release). October 28, 2010.
- ↑ Summary of opinion (initial authorization) . 23rd January 2014.
- ↑ Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda® (lurasidone) , PM by Takeda March 31, 2014, accessed April 1, 2014.
- ↑ Dainippon Sumitomo: Review of overseas development of Lurasidone (SM-13496), an atypical antipsychotic ( Memento of March 22, 2014 in the Internet Archive ) (December 13, 2006, accessed November 1, 2008).
- ↑ Market withdrawals in the course of the AMNOG . December 10, 2015.